Why Wharton’s Jelly May Provide Longer-Lasting Results than PRP
PRP and Wharton’s jelly are both regenerative treatment options that are generally not covered by insurance for orthopedic applications, making cost, comfort, convenience, and expected benefit important considerations.
Wharton’s jelly (WJ) which comes from donated umbilical cords of healthy live births, provides a young-tissue extracellular matrix and signaling environment that is not dependent on the patient’s age, platelet quality, or individual growth-factor profile. In contrast, PRP is produced from the patient’s own blood, so its biologic composition can vary significantly with age, health, platelet function, and preparation technique. WJ provides a more standardized source of extracellular matrix, growth factors, cytokines, hyaluronic acid, and extracellular vesicles that may support a more sustained regenerative and tissue-repair environment, potentially contributing to longer-lasting clinical improvement.
Wharton’s jelly may offer several practical and biologic advantages. Unlike PRP, it does not require a blood draw, centrifugation, or preparation of the patient’s own platelets, making treatment faster and less invasive, and less expensive. WJ also provides a young-tissue extracellular matrix and signaling environment that is not dependent on the patient’s age, platelet quality, health, or individual growth-factor profile.
Individual outcomes vary.
